NY-ESO-1 expression in DCIS: A new predictor of good prognosis

• Published in: Oncoscience Vol. 4; no. 3-4; pp. 33 - 40
• Main Authors: Coombes, R Charles, Caballero, Otavia L, Shousha, Sami, Ghaem-Maghami, Sadaf, Woodley-Barker, Laura, Wilhelm-Benartzi, Charlotte S, Neville, A Munro
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 01.03.2017
• Subjects: Research Paper; breast cancer; ductal-carcinoma-in-situ (DCIS); prognosis; CT antigen; immunotherapy
• ISSN: 2331-4737; 2331-4737
• DOI: 10.18632/oncoscience.348

At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC. 14 of 42 (33%) of patients developed invasive breast cancer during the follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033). We identified 42 patients with DCIS, and followed them up for more than 10 years. NY-ESO-1 and MAGEA were demonstrated by immunostaining as were CD8+ infiltrates on all sections together with the conventional markers, ER, PR, and HER2. Expression of NY-ESO-1 may predict those patients who will not subsequently develop invasive breast cancer and could therefore potentially be helpful in defining prognosis in patients with DCIS.